Daily Health Headlines

End-of-Life Talk Often Comes Too Late for Blood Cancer Patients

👤by Robert Preidt 0 comments 🕔Tuesday, December 22nd, 2015

MONDAY, Dec. 21, 2015 (HealthDay News) -- Many doctors wait too long to have end-of-life discussions with blood cancer patients, a new study finds.

Researchers analyzed surveys completed by 349 blood cancer specialists, and found that 56 percent said end-of-life discussions with patients happen too late.

Nearly 43 percent said they had their first end-of-life discussions with patients at less-than-ideal times, the findings showed. About 23 percent of the doctors said they waited until death was imminent before discussing hospice care. And nearly 40 percent waited until death was imminent before they asked patients where they wanted to die.

Several factors may contribute to the delay in end-of-life discussions with blood cancer patients, according to Dr. Oreofe Odejide, from the Dana-Farber Cancer Institute in Boston, and colleagues.

While solid tumors are incurable after they reach an advanced stage, many advanced blood cancers remain potentially curable. The lack of a clearly defined point when there is no remaining hope for blood cancer patients may contribute to delays in end-of-life discussions, the researchers said.

The study was published online Dec. 21 in the journal JAMA Internal Medicine.

The findings show that blood cancer specialists are aware of gaps in end-of-life care for their patients, but are uncertain how to tackle the issue, Dr. Thomas LeBlanc, from the Duke University School of Medicine in Durham, N.C., explained in an accompanying editorial.

"As a practicing [blood cancer doctor] and a palliative care physician, I believe that the field of hematology should look to specialty palliative care for the answer to this need," he concluded.

-- Robert Preidt

Article Credits / Source

Robert Preidt / HealthDay

Robert Preidt wrote this story for HealthDay. HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCE: JAMA Internal Medicine, news release, Dec. 21, 2015

View More Articles From Robert Preidt 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Cancer Articles

No Benefit From Routine Thyroid Cancer Screening: Task Force

No Benefit From Routine Thyroid Cancer Screening: Task Force0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- Doctors should not screen for thyroid cancer in patients who have no symptoms of the disease, according to a U.S. Preventive Services Task Force draft recommendation. It reaffirms a recommendation ...

Depressed Women Less Likely to Get Best Breast Cancer Care: Study

Depressed Women Less Likely to Get Best Breast Cancer Care: Study0

FRIDAY, Nov. 18, 2016 (HealthDay News) -- Breast cancer patients with a history of depression are less likely to receive recommended care for their disease, a new study finds. The study included more than 45,000 Danish women diagnosed with ...

Earnings Fall After a Child's Cancer Diagnosis

Earnings Fall After a Child's Cancer Diagnosis0

MONDAY, Nov. 21, 2016 (HealthDay News) -- After a child's cancer diagnosis, parents' income often drops and mothers frequently stop working, a new study finds. Moreover, the financial effects of a cancer diagnosis can last years, with mothers' ...

Monoclonal Antibodies

Monoclonal Antibodies0

home / cancer center / cancer a-z list / monoclonal antibodies index / monoclonal antibodies drug monograph Pharmacy Author: Omudhome Ogbru, PharmD Omudhome Ogbru, PharmDDr. Ogbru received his ...

New Drug May Brighten Outlook for Advanced Breast Cancer

New Drug May Brighten Outlook for Advanced Breast Cancer0

WEDNESDAY, Nov. 16, 2016 (HealthDay News) -- A recently approved drug can help slow the progression of advanced breast cancer, a new clinical trial confirms. The drug, called palbociclib (Ibrance), was approved in the United States last year ...

View More Cancer Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!